Ascorbate and endocytosed Motexafin gadolinium induce lysosomal rupture

Cancer Letters

Volumn 307, Issue 2, 2011, Pages 119-123

  Berndt, Carsten ^a,c   Kurz, Tino ^b   Bannenberg, Sarah ^a   Jacob, Ralf ^c   Holmgren, Arne ^a   Brunk, Ulf T ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cancer therapy; Endocytosis; Lysosomes; Oxidative stress; Thioredoxin reductase

Indexed keywords

ASCORBIC ACID; CLATHRIN; GADOLINIUM TEXAPHYRIN; REACTIVE OXYGEN METABOLITE;

ARTICLE; CANCER CELL; CELL LEVEL; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; IRRADIATION; LYSOSOME MEMBRANE; MEMBRANE PERMEABILITY; MEMBRANE RUPTURE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CELL LINE; ENDOCYTOSIS; FLOW CYTOMETRY; HUMANS; LYSOSOMES; METALLOPORPHYRINS; MICROSCOPY, FLUORESCENCE; REACTIVE OXYGEN SPECIES;

EID: 79957655142     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.023     Document Type: Article

References (31)

1. Young S.W., Qing F., Harriman A., Sessler J.L., Dow W.C., Mody T.D., Hemmi G.W., Hao Y., Miller R.A. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA 1996, 93:6610-6615.
2. Magda D., Lepp C., Gerasimchuk N., Lee I., Sessler J.L., Lin A., Biaglow J.E., Miller R.A. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51:1025-1036.
3. Miller R.A., Woodburn K., Fan Q., Renschler M.F., Sessler J.L., Koutcher J.A. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int. J. Radiat. Oncol. Biol. Phys. 1999, 45:981-989.
4. Miller R.A., Woodburn K.W., Fan Q., Lee I., Miles D., Duran G., Sikic B., Magda D. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin. Cancer Res. 2001, 7:3215-3221.
5. Xu S., Zakian K., Thaler H., Matei C., Alfieri A., Chen Y., Koutcher J.A. Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49:1381-1390.
6. Evens A.M. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr. Opin. Oncol. 2004, 16:576-580.
7. Rowinsky E.K. Novel radiation sensitizers targeting tissue hypoxia. Oncology 1999, 13:61-70.
8. Khuntia D., Mehta M. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Exp. Rev. Anticancer Ther. 2004, 4:981-989.
9. Magda D., Gerasimchuk N., Lecane P., Miller R.A., Biaglow J.E., Sessler J.L. Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem. Commun. 2002, 2730-2731.
10. Hashemy S.I., Ungerstedt J.S., Zahedi Avval F., Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem. 2006, 281:10691-10697.
11. Woodburn K.W. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J. Pharmacol. Exp. Ther. 2001, 297:888-894.
12. Kurz T., Eaton J.W., Brunk U.T. Redox activity within the lysosomal compartment: implications for aging and apoptosis. Antioxid. Redox Signal. 2010, 13:511-523.
13. Kurz T., Terman A., Gustafsson B., Brunk U.T. Lysosomes in iron metabolism, ageing and apoptosis. Histochem. Cell Biol. 2008, 129:389-406.
14. Repnik U., Turk B. Lysosomal-mitochondrial cross-talk during cell death. Mitochondrion 2010, 10:662-669.
15. Berndt C., Kurz T., Selenius M., Fernandes A.P., Edgren M.R., Brunk U.T. Chelation of lysosomal iron protects against ionizing irradiation. Biochem. J. 2010, 432:295-301.
16. Persson H.L., Kurz T., Eaton J.W., Brunk U.T. Radiation-induced cell death: importance of lysosomal destabilization. Biochem. J. 2005, 389:877-884.
17. Dunn W.A., Hubbard A.L., Aronson N.N. Low temperature selectively inhibits fusion between pinocytic vesicles and lysosomes during heterophagy of 125I-asialofetuin by the perfused rat liver. J. Biol. Chem. 1980, 255:5971-5978.
18. Weigel P.H., Oka J.A. Temperature dependence of endocytosis mediated by the asialoglycoprotein receptor in isolated rat hepatocytes. Evidence for two potentially rate-limiting steps. J. Biol. Chem. 1981, 256:2615-2617.
19. Wang L.H., Rothberg K.G., Anderson R.G. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J. Cell Biol. 1993, 123:1107-1117.
20. Rodal S.K., Skretting G., Garred O., Vilhardt F., Van Deurs B., Sandvig K. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol. Biol. Cell 1999, 10:961-974.
21. Mosesson Y., Mills G.B., Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat. Rev. Cancer 2008, 8:835-850.
22. Roberts W.G., Palade G.E. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res. 1997, 57:765-772.
23. Pisoni R.L., Acker T.L., Lisowski K.M., Lemons R.M., Thoene J.G. A cysteine-specific lysosomal transport system provides a major route for the delivery of thiol to human fibroblast lysosomes: possible role in supporting lysosomal proteolysis. J. Cell Biol. 1990, 110:327-335.
24. Schafer F.Q., Buettner G.R. Acidic pH amplifies iron-mediated lipid peroxidation in cells. Free Radic. Biol. Med. 2000, 28:1175-1181.
25. Baird S.K., Kurz T., Brunk U.T. Metallothionein protects against oxidative stress-induced lysosomal destabilization. Biochem. J. 2006, 394:275-283.
26. Yu Z., Persson H.L., Eaton J.W., Brunk U.T. Intralysosomal iron: a major determinant of oxidant-induced cell death. Free Radic. Biol. Med. 2003, 34:1243-1252.
27. Chen J., Ramos J., Sirisawad M., Miller R., Naumovski L. Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis. Apoptosis 2005, 10:1131-1142.
28. Zahedi Avval F., Berndt C., Pramanik A., Holmgren A. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem. Biophys. Res. Commun. 2009, 379:775-779.
29. May J.M., Cobb C.E., Mendiratta S., Hill K.E., Burk R.F. Reduction of the ascorbyl free radical to ascorbate by thioredoxin reductase. J. Biol. Chem. 1998, 273:23039-23045.
30. Lincoln D.T., Al-Yatama F., Mohammed F.M., Al-Banaw A.G., Al-Bader M., Burge M., Sinowatz F., Singal P.K. Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. Anticancer Res. 2010, 30:767-775.
31. Yoo M.H., Xu X.M., Carlson B.A., Gladyshev V.N., Hatfield D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 2006, 281:13005-13008.